Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [14C] erythromycin breath and urine test

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 285, Issue 3 48-3, 2003, Pages

  Lemahieu, W P D ^a   Maes, B D ^a   Ghoos, Y ^a   Rutgeerts, P ^a   Verbeke, K ^a   Vanrenterghem, Y ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Breath test; Cytochrome P 450 system; Multiple drug resistance gene product; Renal transplantation

Indexed keywords

CARBON DIOXIDE; CYTOCHROME P450 3A4; ERYTHROMYCIN; ERYTHROMYCIN C 14; GLYCOPROTEIN P; ITRACONAZOLE; RANITIDINE; RIFAMPICIN; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ADULT; ARTICLE; BREATH ANALYSIS; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG INTERACTION; ENZYME ACTIVITY; ENZYME ANALYSIS; HUMAN; INTESTINE MUCOSA; KIDNEY TRANSPLANTATION; LIVER; MATHEMATICAL ANALYSIS; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; URINALYSIS; XENOBIOTIC METABOLISM;

EID: 0042967493     PISSN: 01931857     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpgi.00028.2003     Document Type: Article

References (54)

1. Achira M, Suzuki H, Ito K, and Sugiyama Y. Comparative studies to dermine the selective inhibitors for p-glycoprotein and cytochrome P4503A4. AAPS PharmSci 1: E18, 1999.
2. Ball SE, Scatina JA, Kao J, Ferron GM, Fruncillo R, Mayer P, Weinryb I, Guida M, Hopkins PJ, Warner N, and Hall J. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promotor region of cyp 3A4. Clin Pharmacol Ther 66: 288-294, 1999.
3. Brinkmann U, Roots I, and Eichelbaum M. Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Discov Today 15: 835-839, 2001.
4. Cakaloglu Y, Tredger JM, Devlin J, and Williams R. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK506 and cyclosporine in liver transplant recipients. Hepatology 20: 309-316, 1994.
5. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, and Kim RB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27: 866-871, 1999.
6. Damkier P, Hansen LL, and Brosen K. Rifampicin treatment greatly increases the apparent oral clearance of quinidine. Pharmacol Toxicol 85: 257-262, 1999.
7. De Wildt SN, Kearns GL, Leeder JS, and van den Anker JN. Cytochrome P450 3A ontogeny and drug disposition. Clin Pharmacokinet 37: 485-505, 1999.
8. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, and Kim RB. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71: 11-20, 2002.
9. Edwards DJ, Fitzsimmons ME, Schuetz EG, Yasuda K, Ducharme MP, Warbasse LH, Woster PM, Schuetz JD, and Watkins PB. 6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther 65: 237-244, 1999.
10. Ghoos YF, Maes BD, Geypens BJ, Mys G, Hiele MI, Rutgeerts PJ, and Vantrappen G. Measurement of gastric emptying rate of solids by means of by means of a carbon labelled octanoic breath test. Gastroenterology 104: 1640-1647, 1993.
11. Guengerich FP. Pharmacogenomics of cytochrome P450 and other enzymes involved in biotransformation of xenobiotics. Drug Dev Res 49: 416, 2000.
12. Guengerich FP. Characterisation of human cytochrome P450 enzymes. FASEB J 6: 745-48, 1992.
13. Guo LQ, Fukuda K, Ohta T, and Yamazoe Y. Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human Cyp3A activity. Drug Metab Dispos 28: 766-771, 2000.
14. Hall SD, Thummel KE, Watkins PB, Lown KS, Benet LZ, Paine MF, Mayo RR, Turgeon DK, Bailey DG, Fontana RJ, and Wrighton SA. Molecular and physical mechanisms of first pass extraction. Drug Metab Dispos 27: 161-166, 1999.
15. Hamman MA, Bruce MA, Haehner-Daniels BD, and Hall SD. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 69: 114-121, 2001.
16. Haycock G, Schwartz G, and Wisotsky D. Geometric method for measuring body surface area: a height-weight formula validated in infants, children and adults. J Pediatr 93: 62-66, 1978.
17. Hebert MF, Fisher RM, Marsh CL, Dressler D, and Bekersky I. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 39: 91-96 1999.
18. Hebert MF, Roberts JP, Prueksaritanont T, and Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 52: 453-457, 1992.
19. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, and Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97: 3473-3478, 2000.
20. Ioannides-Desmos LL, Christophidis N, Ryan P, Angelis P, Liolios L, and McLean AJ, Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases. J Rheumatol 24: 49-54, 1997.
21. Janssens J, Peeters TL, Vantrappen G, Tack J, Urbain JL, De Roo M, Muls E, and Bouillon R. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med 322: 1028-1031, 1990.
22. Kange GC and Lipsky JJ. Drug-grapefruit juice interactions. Mayo Clin Proc 75: 933-942, 2000.
23. Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 34: 47-54, 2002.
24. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJJ, and Wilkinson GR. Interrelationship between substrates and inhibitors of human cyp3A4 and P-glycoprotein. Pharm Res 16: 408-414, 1999.
25. Krecic-Shepard ME, Barnas CR, Slimko J, Gorski JC, Winer IW, and Schwartz JB. In vivo comparison of putative probes of CYP 3A4/5 activity: eryhromycin, dextromethorphan and verapamil. Clin Pharmacol Ther 66: 40-50, 1999.
26. Krivoruk Y, Kinirons MT, Wood AJJ, and Wood M. Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test. Clin Pharmacol Ther 56: 608-614, 1994.
27. Ku MY, Min DI, and Flanigan M. Effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: does the formulation difference matter? J Clin Pharmacol 38: 959-965, 1998.
28. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, and Schuetz E. Sequence diversity in Cyp3A promoters and characterization of the genetic basis of polymorphic cyp 3A5 expression. Nat Genet 27: 383-391, 2001.
29. Lo A and Burckart GJ. P-glycoprotein and drug therapy in organ transplantation. J Clin Pharmacol 39: 995-1005, 1999.
30. Lown K, Kolars J, Turgeon K, Merion R, Wrighton SA, and Watkins PB. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther 51: 229-238, 1992.
31. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, and Watkins PB. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 99: 2545-2553, 1997.
32. Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK, Berent S, and Watkins PB. The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 57: 16-24, 1995.
33. Lundahl JU, Regardh CG, Edgar B, and Johnsson G. The interaction effect of grapefruit juice is maximal after the first glass. Eur J Clin Pharmacol 54: 75-81, 1998.
34. Maes BD, Mys G, Geypens BJ, Evenepoel P, Ghoos Y, and Rutgeerts PJ. Gastric emptying flow curves separated from carbon-labeled octanoic acid breath test results. Am J Physiol Gastrointest Liver Physiol 275: G169-G175, 1998.
35. Malhotra S, Bailey DG, Paine MF, and Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther 69: 14-23, 2001.
36. McKinnon RA, Burgess WM, Hall PM, Roberts-Thomson SJ, Gonzalez FJ, and McManus ME. Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut 36: 259-267, 1995.
37. Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, and Hunsicker LG. Effect of grapefruit juice on cyclosporin pharmacokinetics in renal transplant patients. Transplantation 62: 123-125, 1996.
38. Paine MF, Khalighi M, Fischer JM, Shen DD, Kuknze KL, Marsh CfL, Perkins JD, and Thummel KE. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283: 1552-1562, 1997.
39. Paine MF, Wagner DA, Keith A, Hoffmaster BS, and Watkins PB. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin. Clin Pharmacol Ther 72: 524-535, 2002.
40. Schuetz EG, Beck WT, and Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49: 311-318, 1996.
41. Sobh MA, Hamdy AF, El Agroudy AE, El Sayed K, El-Diasty T, Bakr MA, and Ghoneim MA. Coadministration of ketoconazole and cyclosporine for kidney transplantation recipients: long-term follow-up and study of metabolic consequences. Am J Kidney Dis 37: 510-517, 2001.
42. Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, and Benet LZ. Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res 16: 478-485, 1999.
43. Strayhorn VA, Baciewicz AM, and Self TH. Update on rifampin drug interactions. Arch Intern Med 157: 2453-2458, 1997.
44. Streetman DS, Bertino JS, and Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10: 187-216, 2000.
45. Sudhir G, Jungmee K, and Sastry G. Reversal of daunorubicin resistance in P388/ADR cells by itraconazole. J Clin Invest 87: 1467-1469, 1991.
46. Tanaka E and Breimer DD. In vivo function tests of hepatic drug-oxidizing capacity in patients with liver disease. J Clin Pharm Ther 22: 237-249, 1997.
47. Tanigawara Y. Role of P-glycoprotein in drug disposition. Ther Drug Monit 22: 137-140, 2000.
48. Turgeon DK, Leichtman AB, Lown KS, Normoll DP, Deeb GM, Merion RM, and Watkins PB. P450 3A activity and cyclosporine dosing in kidney and heart transplant patients. Clin Pharmacol Ther 56: 253-260, 1994.
49. Ueda K, Yoshida A, and Amachi T. Recent progress in P-glycoprotein research. Anticancer Drug Des 14: 115-121, 1999.
50. Van der Valk P, van Kalken CK, Ketelaars H, Broxterman HJ, Scheffer G, Kuiper CM, Tsuruo T, Lankelma J, Meijer CJLM, Pinedo HM, and Scheper RJ. Distribution of multidrug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Ann Oncol 1: 56-64, 1990.
51. Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, and Wood AJJ. P-glycoprotein and cytochrome P-450 inhibition: dissociation of inhibitory potencies. Cancer Res 59: 3944-3948, 1999.
52. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, and Guzelian PS. Erythromycin breath test asan assay of glucocorticoid-inducible liver cytochromes P450. J Clin Invest 83: 688-697, 1989.
53. Wilkinson GR. Cytochrome P4503A metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 24: 475-490, 1996.
54. Young VR and Ajami AM. Isotopic metaprobes, nutrition, and the roads ahead. J Parent Ent Nutr 23: 175-194, 1999.